Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2017 · 10-Q
Revenue$264.00K$264.00K−36.1% vs Q3 2016 Net Income-$7.74M-$7.74MN/M vs Q3 2016 EPS Diluted-$0.43-$0.43N/M vs Q3 2016 Operating Income-$8,644,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,640,000N/M Margins · derivedOperating margin-3274.2%−1499.2 pt vs Q3 2016
Net margin-2932.6%−1064.8 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end